ArticleClinical and experimental hepatology2025
Association between metabolic associated fatty liver disease and HCC risk after SVR in HCV patients: A systematic review and meta-analysis.
Article in Clinical and experimental hepatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Retrospective Analysis of Diagnostic and Prognostic Value of Serum Glypican-3 in Patients With HCV-Related Cirrhosis With Or Without HCC After Achieving SVR With DAA Treatment.Journal of gastrointestinal cancer · 2026Observational
- Precision Strategy for Hepatocellular Carcinoma Surveillance after Hepatitis C Cure: Debates across Guidelines.Gut and liver · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim of the study: Chronic hepatitis C (CHC) infection remains one of the most prevalent chronic liver disease worldwide. A sustained virological response (SVR) can be achieved at high rates for CHC patients receiving direct-acting antivirals (DAAs). However, even small subsets of patients achieving SVR still have a risk of developing hepatocellular carcinoma (HCC). Metabolic-associated fatty liver disease (MAFLD) is associated with increased risk of HCC. We aimed to summarize the effect of MAFLD on HCC development on CHC patients, even after achieving SVR. Material and methods: We conducted a search of PubMed and Google Scholar from inception to July 7 Results: Five studies with a total of 7,034 patients were included. The quality of studies ranged from 6 to 8 stars. Metabolic dysfunction is associated with increased risk of HCC after SVR in CHC patients (HR = 2.02, 95% CI: 1.61-2.54, Conclusions: Metabolic dysfunction is associated with increased risk of HCC progression in CHC patients even after achieving SVR.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.